BMO vs CM

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like a 38.67% operating margin and strong revenue growth of 15.50%, earnings growth is inconsistent, with recent Q/Q declines and volatile quarterly surprises. The stock trades above its Graham defensive value of $127.87 at $137.69, yet below the analyst target of $127.91, while offering a solid 3.45% dividend yield with a sustainable 56.29% payout ratio. Technical trend sentiment is weak at 10/100, offsetting positive insider sentiment, resulting in a neutral overall stance.

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating significant deterioration in fundamental financial strength. While the company exhibits explosive growth (Earnings +46.6% YoY) and a strong track record of earnings beats, these are countered by a severely bearish technical trend (10/100) and a current price that has already exceeded analyst target prices. The stock trades at a premium to its Graham Number ($89.37) but remains well below its growth-based intrinsic value ($207.09), suggesting a conflict between short-term health risks and long-term growth potential.